4 results match your criteria: "The University of California Davis Comprehensive Cancer Center[Affiliation]"
Purpose: To assess the effect of clinical and pathological variables on cancer-specific and overall survival (OS) in de novo metastatic patients from a collaborative of primarily Latin American countries.
Patients And Methods: Of 4,060 patients with renal cell carcinoma diagnosed between 1990 and 2015, a total of 530 (14.5%) had metastasis at clinical presentation.
Bipolar androgen therapy: an intriguing paradox.
Lancet Oncol
January 2018
Department of Urology, University of California Davis School of Medicine and the University of California Davis Comprehensive Cancer Center, Sacramento, CA 95817, USA. Electronic address:
Renal-Cell Cancer--Targeting an Immune Checkpoint or Multiple Kinases.
N Engl J Med
November 2015
From the University of Southern California Norris Comprehensive Cancer Center, Los Angeles (D.I.Q.), and the University of California Davis Comprehensive Cancer Center, Sacramento (P.N.L.).
Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors.
Clin Cancer Res
June 2015
The University of California Davis Comprehensive Cancer Center, Sacramento, California.
Purpose: This phase I study examined the toxicity and tolerability of pegylated arginine deiminase (ADI-PEG 20) in combination with docetaxel in patients with advanced solid malignancies.
Experimental Design: Eligible patients had histologically proven advanced solid malignancies, with any number of prior therapies, Zubrod performance status 0-2, and adequate organ function. Patients received ADI-PEG 20 weekly intramuscular injection ranging from 4.